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iagnostic ultrasound contrast agents have been
developed for enhancing the echogenicity of blood
and for delineating other structures of the body.
Approved agents are suspensions of gas bodies (sta-
bilized microbubbles), which have been designed for persis-
tence in the circulation and strong echo return for imaging. The
interaction of ultrasound pulses with these gas bodies is a form
of acoustic cavitation, and they also may act as inertial cavitation
nuclei. This interaction produces mechanical perturbation and a
potential for bioeffects on nearby cells or tissues. In vitro, sono-
poration and cell death occur at mechanical index (MI) values
less than the inertial cavitation threshold. In vivo, bioeffects
reported for MI values greater than 0.4 include microvascular
leakage, petechiae, cardiomyocyte death, inflammatory cell infil-
tration, and premature ventricular contractions and are accompa-
nied by gas body destruction within the capillary bed. Bioeffects
for MIs of 1.9 or less have been reported in skeletal muscle, fat,
myocardium, kidney, liver, and intestine. Therapeutic applica-
tions that rely on these bioeffects include targeted drug delivery
to the interstitium and DNA transfer into cells for gene therapy.
Bioeffects of contrast-aided diagnostic ultrasound happen on a
microscopic scale, and their importance in the clinical setting
remains uncertain. Key words: acoustic cavitation; contrast
agent adverse effects; echocardiography; mechanical index.
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1. Introduction
The ability to “see” inside the body represents one
of the most potent diagnostic tools of modern
medicine. Ultrasound imaging is particularly attrac-
tive owing to the portability of imaging machines and
the inherent safety of low-power acoustic interroga-
tion of tissue. The desire for means to enhance image
information has led to the development of contrast
agents for pulse-echo diagnostic ultrasound, as for
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other imaging modalities (ie, radiography and
magnetic resonance imaging). Although similar
in concept to radiologic contrast agents, ultra-
sound contrast agents have unique properties
designed for echogenic interaction with the
ultrasonic pulses, which make them special
cases for safety assurance in diagnosis.
The primary purpose of ultrasound contrast
agents is to enhance the echogenicity of blood.
Although modern Doppler imaging equipment
is very good at showing the location and motion
of rapidly flowing blood, it fails in other impor-
tant diagnostic problems such as capillary per-
fusion. What could reasonably be added to
blood to enhance its echogenicity? The answer is
microbubbles. Over the past 2 decades, contrast
agents consisting of suspensions of gas bodies
(specially stabilized microbubbles) have been
developed that can pass through the lungs after
intravenous injection and persist in circulation
for useful periods.1–3 Ultrasound contrast agents
can enhance B-mode and Doppler images, and
special imaging methods can show blood distri-
bution at the capillary level to reveal tissue perfu-
sion.4 Owing to the promise of safe and more
cost-effective vascular diagnosis than might be
possible with contrast-enhanced radiography or
magnetic resonance imaging, a substantial
research and development effort has been pur-
sued to achieve approval and bring ultrasound
contrast agents to the clinic.
The interaction of ultrasound with gas bodies
for enhanced echogenicity also introduces a
potential for bioeffects. Ultrasonic cavitation is
defined as the interaction of ultrasound with a
body of gas and is a potent mechanism for bio-
logical effects of ultrasound.5,6 Cavitation involv-
ing microbubbles (microcavitation) has long
been recognized as the most likely potential
mechanism for nonthermal bioeffects of diag-
nostic ultrasound.7,8 At the megahertz frequen-
cies used for diagnostic ultrasound, the most
efficiently echogenic (ie, resonant) gas bodies
are a few (≈1–5) micrometers in diameter. At
low ultrasonic pressure amplitudes, less than
atmospheric pressure (0.1 MPa), cavitation
microbubbles pulsate linearly in response to the
time-varying acoustic pressures of the ultra-
sound field. At higher pressure amplitudes, the
pulsation becomes nonlinear, and expansion
during the rarefactional pressure phase may
become much greater than the initial microbub-
ble radius. The large expansions are followed
by violent collapse of the microbubble, in which
the collapse is dominated by the inertia of the
inrushing fluid surrounding the microbubble.
For this reason, this special case of ultrasonic
cavitation is called inertial cavitation. The mini-
mum threshold for inertial cavitation was calcu-
lated for the diagnostically relevant frequency
range,9 and this theory served as the basis for the
mechanical index (MI) used for display on ultra-
sound imaging machines.10
Gas bodies suitable for nucleation of ultrasonic
cavitation are normally practically absent from
the body, minimizing the possibility of cavitation-
al bioeffects for diagnostic ultrasound without
contrast agents.6 The fortuitous coincidence that
the microbubble sizes most strongly activated by
diagnostic ultrasound pulses to yield high
echogenicity are small enough to pass through
the circulatory system has allowed the creation of
ultrasound contrast agents. However, the use of
gas body contrast agents introduces a potential
for microcavitation bioeffects into the clinical
diagnostic setting. At low MIs, the stabilized
microbubbles scatter ultrasound effectively, but
the amplitudes of oscillation are too small to have
significant effects on nearby cells. At higher MIs,
the contrast agent microbubbles may be destabi-
lized, allowing loss of the gas or nucleation of
microcavitation activity.11 This destabilization
process can be useful for certain diagnostic pro-
cedures but can also damage nearby cells. The
bioeffects possible with contrast agents and diag-
nostic ultrasound are sufficiently robust that sev-
eral therapeutic applications are under study.12
The subject considered in this report is the
potential for contrast-enhanced diagnostic ultra-
sound to induce cavitational bioeffects by ultra-
sound interaction with the gas bodies. This
potential has been the subject of authoritative
reviews previously.5,6 In addition, a symposium
on the safe use of ultrasound contrast agents was
conducted recently by the World Federation for
Ultrasound in Medicine and Biology.13 This
report arose from the 2005 American Institute of
Ultrasound in Medicine Bioeffects Consensus
Conference. Aspects of this subject considered
below include (1) the nature of present contrast
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agents, including diagnostic applications and
ultrasound imaging modes; (2) the basic in vitro
bioeffects of contrast gas body activation; and (3)
reported in vivo bioeffects, including the thera-
peutic potential of contrast-enhanced diagnostic
ultrasound. The text will only briefly revisit infor-
mation included in the earlier conference report5
and will concentrate on bioeffects data relevant to
diagnostic imaging, which have become available
between 1998 and the 2005 conference. Summary
conclusions are then presented with recommen-
dations intended to optimize the safety profile of
contrast-aided diagnostic ultrasound.
2. Contrast Agents for Diagnostic
Ultrasound
2.1. Ultrasound Contrast Agents
First-generation contrast agents used air as the
core gas. These air bubbles were surrounded by a
fatty acid, lipid, or protein shell. The shell sur-
rounding the air bubble increased the stability of
the microbubbles both in the vial and in the
body. Commercially available first-generation
agents included Echovist (SH U 454; Schering AG,
Berlin, Germany), Levovist (SH U 508A;, Schering
AG), both of which were only available in Europe,
and Albunex (Molecular Biosystems, Inc, San
Diego, CA), which was the first agent approved by
the US Food and Drug Administration (FDA) for
use in the United States.
One of the problems with the first-generation
microbubbles was the short duration of efficacy
after intravenous injection. These first-genera-
tion agents used air as the active component.
However, because of an inherent unsaturation of
dissolved gases (primarily oxygen, nitrogen, and
carbon dioxide) in blood, the air contained with-
in these contrast agents readily diffused out of
the microspheres or microbubbles.14 With this
loss of air, the first-generation contrast agents
quickly lost the ability to produce ultrasound
contrast. The next advancement made in ultra-
sound contrast agents (the second generation)
was the inclusion of gases having decreased
solubility and diffusivity. These microspheres
or microbubbles retain their gas for a longer
period of time; thus, the durations of contrast
and Doppler enhancement increase from sever-
al seconds to several minutes.15
Optison (FS-069, perflutren protein type A
microspheres for injection; GE Healthcare,
Princeton, NJ) was the first second-generation
ultrasound contrast agent approved by the FDA.
This agent consists of a protenaceous shell sur-
rounding a gas bubble of octafluoropropane gas.16
This relatively insoluble gas is inert and eliminat-
ed through normal gas exchange in the lung.
Optison opacifies the cardiac ventricular cham-
bers at doses much smaller than Albunex (0.2 mL
compared with 15–20 mL, respectively) and
opacifies the chamber for a much longer period of
time than Albunex (>5 minutes versus 30–45 sec-
onds).17 Currently, Optison is indicated to opacify
the left ventricular chamber and to improve the
delineation of the endocardial border.
Definity (MRX-115, perflutren lipid micro-
spheres; Bristol-Myers Squibb Medical Imaging,
North Billerica, MA) is another agent that encap-
sulates octafluoropropane, but this agent uses
phospholipids to coat the microbubbles. Before
injection, Definity must be activated by agitation
in a “dental shaker” for approximately 45 seconds.
Small volumes of these microbubbles opacify the
left ventricular chamber and enhance the Doppler
signal from the peripheral vasculature for pro-
longed periods of time.18,19 The microvascular rhe-
ology of Definity microspheres has been shown to
be similar to that of erythrocytes in the circula-
tion.20 Currently in the United States, Definity is
indicated for opacification of the left ventricular
chamber and to improve the delineation the endo-
cardial border. In Canada, Definity is indicated for
both cardiology and radiology applications.
Imagent (AFO150, perflexane lipid micro-
spheres; IMCOR Pharmaceuticals, San Diego, CA)
is another ultrasound contrast agent that uses a
perfluorocarbon to increase in vivo stability. This
agent is composed of phospholipids, phosphate
buffers, sodium chloride, and a blend of perfluo-
rohexane and nitrogen.21 As with the other two
approved agents, Imagent is indicated for opacifi-
cation of the left ventricular chamber and to
improve delineation of the endocardial borders.
Although not approved for sale in the United
States, SonoVue (BR-1, sulfur hexafluoride; Bracco
International BV, Amsterdam, the Netherlands) is
also a second-generation ultrasound contrast
agent approved for use in Europe. This agent is
composed of phospholipids, ethylene glycol,
J Ultrasound Med 2008; 27:611–632 613
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and sulfur hexafluoride gas.22 Originally,
SonoVue was approved in March 2001 to
increase the echogenicity of the blood, opacify
the cardiac chambers, improve delineation of the
endocardial borders, improve the Doppler signal-
to-noise ratio in the cerebral, extracranial carotid,
and peripheral arteries, and improve the visual-
ization of the vascularity of liver and breast
lesions (SonoVue package insert). In May 2004,
the European Medicines Agency restricted the
use of SonoVue to noncardiac imaging proce-
dures.23 This restriction was later removed, and a
precautionary statement was issued stating that
extra caution should be exercised in patients with
conditions such as severe hypotension, bradycar-
dia, cardiac arrest, and myocardial infarction.
The second-generation ultrasound contrast
agents relied on core gases that possessed low
solubility in blood to prolong their duration in
the circulation. A third generation of contrast
uses engineered changes in the microsphere
shell to impart unique features to the contrast
materials. Although these agents are still in
development, two are in the later stages of their
initial clinical development.
CARDIOsphere (PB127; Point Biomedical Corp,
San Carlos, CA) is composed of a bilayer shell made
up of polylactide and albumin. The polylactide
inner layer is a biodegradable polymer that pro-
vides specific physical characteristics, which con-
trol acoustic properties of the contrast agent. The
outer layer, composed of human albumin, func-
tions as the biological interface and provides bio-
compatibility. These microspheres use nitrogen as
the gas core. They were designed to collapse under
very specific ultrasound conditions.24 Once the
microspheres are destroyed, the encapsulated
nitrogen is released, and the gas quickly dissolves
into the surrounding blood. This rapid loss of gas
produces an intense signal using harmonic power
Doppler imaging techniques.25 Another third-gen-
eration agent, AI-700 (Acusphere, Inc, Watertown,
MA), uses a synthetic porous microparticle to trap
an insoluble gas. These microparticles are com-
posed of D,L-lactide co-glycolide, a biodegradable
polymer. These microparticles appear to be more
resistant to the destructive effects of ultrasound.26,27
Several companies continue to develop new
ultrasound contrast agents with unique proper-
ties and niche applications. Their developmental
status, physical characteristics, and imaging pro-
files are less well known. A description of these
various materials must wait until they move fur-
ther along the developmental pathway. In
addition, several other agents (eg, Ecogen,
[Sonos Pharmaceuticals, Bothell, WA], Sonazoid
[Nycomed, Zurich, Switzerland], Sonovist
[Schering AG], and Quantison [Andaris Ltd,
Nottingham, England]) failed to make it through
the entire developmental process and gain regula-
tory approval for one reason or another. Although
these agents did not make it to the clinical market,
the information derived from their use both pre-
clinically and clinically has contributed to a better
overall understanding of ultrasound contrast
agents, their effects and their applications.
2.2. Diagnostic Applications of Ultrasound
Contrast Agents
Echocardiographic applications for Optison,
Definity, and Imagent approved for use in the
United States include left ventricular opacification
and border delineation. Contrast echocardiogra-
phy can also be used (but is not yet approved in
the United States) for measurement of myocardial
perfusion.28 Levovist and SonoVue are used in
other countries for cardiac, microvascular, and
transcranial indications. Possibly the most promi-
nent clinical application of contrast agents in
Canada, Europe, and Asia is the detection and
characterization of liver lesions. There are many
other potential applications for imaging, includ-
ing tissue perfusion, inflammation, and tumors, in
any tissue accessible to ultrasound interrogation,
including liver, kidney, breast, spleen, and oth-
ers.29–31 Ultrasound contrast agents are useful also
for imaging body structure and function, such as
for the diagnosis of vesicoureteral reflux32,33 and
fallopian tubal patency.34,35
2.3. Diagnostic Ultrasound Modes Used With
Contrast Agents
Ultrasound imaging enhanced by the use of
ultrasound contrast agents has been the subject
of several recent reviews.36–38 Ultrasound con-
trast agents can be used most simply by bolus
injection or infusion to enhance the echogenici-
ty of blood in B-mode or Doppler images. High MI
values, such as those used for harmonic imaging
without contrast agents, result in the destruction
614 J Ultrasound Med 2008; 27:611–632
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of the contrast agent and loss of contrast. This
property of contrast agents has been used by inter-
mittent imaging with agent infusion, which allows
the tissue vasculature to refill with the contrast
agent before the next image frame is processed (eg,
see Porter et al39 and Kuersten et al40). This proce-
dure can be used to image perfusion by varying the
interframe trigger timing, as for myocardial con-
trast echocardiography (MCE).41 Doppler tech-
niques are well suited to image microbubble
destruction. Harmonic power Doppler imaging
combined with some form of triggering has been
used extensively to image microbubbles in the
macrocirculation and microcirculation.
The increased sensitivity provided by newer
imaging techniques makes it possible to image
contrast microbubbles relatively nondestructively
in real time at very low acoustic pressures. Low-MI
imaging is important for two reasons. First, at a
low MI, bubble destruction is avoided. Although
microbubbles differ in their shell composition,
work completed to date indicates that at an MI of
about 0.15, the microbubbles examined are not
significantly destroyed yet give a good harmonic
(nonlinear) contrast signal.37 The second major
reason for low-MI scanning is the reduction of the
harmonic component in the tissue echoes relative
to bubble echoes. While tissue harmonics have
benefited routine diagnostic scanning, it is the
background “noise” signal that the contrast signal
must rise above. Because tissue is less nonlinear
than bubbles, it requires a higher MI than the con-
trast microbubbles for a certain harmonic
response. Therefore, at a low MI, the contrast-to-
tissue ratio is higher than at a high MI, helping
remove the tissue signal and leave only the con-
trast. For quantification purposes, both high and
low MIs may be combined, in which a high-MI
pulse is sent to destroy the contrast microbubbles
in a scan plane, and then a low MI is used after-
ward to monitor the contrast replenishment.
3. Ultrasound Interaction With Contrast
Agent Gas Bodies: Physical Theory
3.1. Pulsation
The physical interaction between ultrasound
pulses and contrast agent gas bodies produces
microbubble pulsations, which are responsible
for their high echogenicity but which also increase
the potential for local bioeffects. Theory has been
developed for the interaction of ultrasound with
encapsulated gas bubbles in contrast agents such
as Optison.42,43 The theory is similar to that for a
free cavitation microbubble but with added elas-
ticity and viscosity-related damping parameters
to account for the shell. This theory has been
used to describe the scattering properties of sus-
pensions of the agents, leading to empirical val-
ues for the shell parameters.44 The theories
appear to be reasonable models of the gas body
behavior for low levels of excitation. In addition,
the presence of blood cells around the contrast
agent gas bodies has a relatively small effect on the
theoretical dynamics of the pulsation.45
3.2. Influence of Contrast Agents on Tissue
Heating
Although thermal effects of ultrasound are treat-
ed in other articles,46,47 the presence of contrast
agents may have an effect on tissue heating. The
theory for this effect has been advanced48 and
tested in nonbiological materials such as tissue-
mimicking phantoms.49 Because of the ability of
bubbles to oscillate nonlinearly and produce
higher-frequency components than are present
in the insonifying beam, acoustic energy can be
dissipated much more effectively as heat.
Moreover, the effects of fluid viscosity near oscil-
lating bubbles are enhanced because of the large
component of acoustic radiation (especially for
bubbles above the resonance size50). Numerical
modeling of the theory agrees reasonably well
with in vitro experiments.51–53 In addition, Stride
and Saffari54 have noted that the viscous proper-
ties of the stabilizing shells could enhance local
heating near the gas bodies.
Measurements of excess heating of tissue due
to the presence of echo contrast agents fall most-
ly in the insonification regimen of therapeutic
ultrasound. Fujishiro et al55 insonified beef sam-
ples using 1.5-MHz continuous ultrasound at 0.9
W/cm2 for 3 minutes and found an equivalent
temperature rise to doubling the intensity with-
out contrast agents present. Wu56 found excess
temperature elevation of several degrees Celsius
due to the presence of contrast agents in suspen-
sions insonified at 3.5 W/cm2 and 1 MHz. Sokka et
al57 monitored lesion formation in rabbit thighs
after bubbles were detected following a 7-W con-
J Ultrasound Med 2008; 27:611–632 615
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tinuous insonation at 1.7 MHz for 20 seconds.
The lesions were larger in volume by up to a fac-
tor of 3 for the bubble-enhanced exposures.
3.3. Cavitation Nucleation
At low pressure amplitudes, the contrast agent
gas bodies may remain stable; that is, their
shells may remain intact as the gas body oscil-
lates. However, destabilization of gas bodies
appears to occur at modest peak rarefactional
pressure amplitudes (PRPAs), particularly for
shell-encapsulated designs. At relatively high
pressure amplitudes, the stabilized gas bodies
are destroyed but can serve as cavitation nuclei.
As the incident ultrasound pressure amplitude
increases from 0, the stabilizing shell experi-
ences oscillating stresses. Above rather modest
excitation PRPAs, the theoretical stresses may
be sufficient to expect shell failure.58 From in
vitro bioeffects research on contrast agents, it is
evident that bioeffects are often associated with
gas body destabilization, and that observation
of the loss of gas bodies appears to agree with
the theory for expected shell failure as a func-
tion of frequency.59 Uncertainty remains as to
how the theories can be used to describe the
destabilization of the gas bodies and the com-
plex behavior at higher amplitudes. The fate of
destabilized gas bodies can include gradual
shrinkage or rapid fragmentation, depending
on physical conditions.60,61
Nucleation of cavitation involves a transition
from restricted pulsation of gas bodies to the free
pulsation of cavitation microbubbles. Cavitation
nucleation by ultrasound contrast agents is
important with regard to the bioeffects potential
in vivo because there normally are few, if any,
cavitation nuclei in the body suitable for direct
activation by diagnostic ultrasound pulses.62
Ultrasound contrast agents can supply such
nuclei. For example, direct evidence of cavita-
tional activity has been obtained by detection of
broadband noise emissions from the myocardi-
um during contrast echocardiography.63
At relatively modest PRPAs, the pulsation of free
microbubbles results in collapse driven by the
inertia of the surrounding liquid during the com-
pression phase of the oscillation. This phe-
nomenon defines inertial cavitation, which is
strongly associated with many bioeffects. These
bioeffects are caused by fluid jets, extreme heat-
ing, and free radicals generated on collapse.5 The
threshold for inertial cavitation derived for opti-
mum-sized nuclei was the basis for the MI. By
assuming the presence of these optimally sized
nuclei, the inertial cavitation threshold p for
blood at frequency f was found to fit the formula9
The square root of this formula approximates the
form of the MI (ie, the PRPA in MPa divided by
the square root of the frequency in megahertz).
The minimum inertial cavitation threshold in
blood can therefore be expressed approximately
in terms of the MI as MIt = 0.4. As noted below in
section 5, several in vivo bioeffects associated
with contrast-aided diagnostic ultrasound have
been reported at and above this MI value,
although the frequency dependence of ultra-
sound bioeffects thresholds in the presence of an
echo contrast agent may differ from that suggest-
ed by the MI (see Figure 1). 
3.4. Shear Stress Theory for Bioeffects
Bioeffects induced by ultrasound interaction
with contrast agents are amenable to theoretical
consideration. However, detailed theory for esti-
mating the amount of biological perturbation
expected from a given exposure situation is not
presently available for use in medical applications
of contrast agents. Even for moderate pressure
amplitudes, a number of different mechanisms
may plausibly have a role in bioeffects.64 Large
oscillatory and steady fluid shear stresses occur for
gas body pulsation near solid surfaces. The con-
trast agent gas bodies can destabilize and nucleate
inertial cavitation. Cavitation, in the absence of
contrast agents, is rare in most tissues and is dis-
cussed in other conference reports.65,66 However,
the use of ultrasound contrast agents introduces
the potential for cavitational bioeffects into the
risk/benefit equation for diagnostic ultrasound.
For low PRPAs and simple in vitro conditions,
cellular bioeffects have been modeled theoreti-
cally with some success. Fluid shear stress gener-
ated in the vicinity of a pulsating gas body can
produce mechanical membrane damage.67,68 The
microstreaming shear stress model has proven
useful in describing several bioeffects situations
13. .0
67.1
=
f
p
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involving gas body activation in terms of the dam-
age of cell membranes by shear stress in acoustic
microstreaming fluid flow near the oscillating gas
body.69 Approximate theory is available for the
nonoscillatory steady shear stress generated in
near-boundary acoustic microstreaming and can
be used to estimate the pressure amplitudes
required to exceed the critical shear stress for bio-
logical membranes. The average steady stress can
also persist with a time-average value given by the
peak stress times the fractional duty cycle. Miller70
considered this theoretical model with respect to
ultrasound contrast agents. Significant shear stress
was found to be possible for relatively low pressure
amplitudes, particularly for the case of free
microbubbles. The pressure amplitude for which
the shear stress was expected to exceed critical lev-
els increased approximately in proportion to fre-
quency for encapsulated gas bodies. Wu71 used the
microstreaming shear stress theory to model the
effects of contrast agent gas bodies attached to
cells when exposed to ultrasound. Shear stresses
generated by 1- to 2-MHz ultrasound were found
to be sufficient for sonoporation (transient perme-
abilization with resealing) of cells at a pressure
amplitude of only 0.12 MPa. Destabilization with
liberation of free bubbles was shown to produce a
much higher shear stress with potential cell killing.
The shear stress model was applied to a specific
experimental system for which contrast agent gas
bodies were exposed to pulsed ultrasound while
attached to monolayer cells.72,73 The observed
PRPA thresholds p for destabilization at different
ultrasound frequencies f correspond to approxi-
mately constant relative pulsation amplitudes
(amplitude divided by the initial radius). The con-
stant relative amplitudes theoretically yield
approximately constant shell stresses, which were
sufficient to induce destabilization. The observed
cell death thresholds corresponded theoretically to
approximately constant radial velocity ampli-
tudes. The constant velocity amplitudes theoreti-
cally yield slowly increasing microstreaming shear
stress for 1.8- to 0.2-microsecond pulse durations
in the 1- to 10-MHz range. For this model system,
contrast agent gas body destabilization and pulsa-
tion-induced cell membrane damage was expect-
ed to occur for similar critical values of the
parameter p/f. The comparison to in vitro bioef-
fects is noted below in section 4.2.
4. Basic In Vitro Studies of Bioeffects
Potential
In vitro experimental models can provide
insights into the fundamental processes and
minimum ultrasound exposures needed for bio-
effects induced by the interaction of ultrasound
with contrast agents. There are two qualitatively
different situations for cultured cells: suspen-
sions and monolayers. Selected PRPA values for
thresholds of in vitro bioeffects are plotted as a
function of frequency in Figure 1. 
4.1. Effects Produced in Cell Suspensions
Sonolysis of red blood cell suspensions (or
hemolysis) containing contrast agent gas bodies
has been studied extensively.5 The frequency
dependence of thresholds for hemolysis in
whole blood with added Albunex in a stationary
chamber was determined by Miller et al74 for
pulsed (10-microsecond pulses) ultrasound
(Figure 1). The threshold at 2.4 MHz with
Optison was found to be somewhat lower,
presumably due to the greater presence of the
microbubbles.75
A correlation between contrast-aided-ultra-
sound induced hemolysis in a rotating cham-
ber and the amount of passively detected
inertial cavitation activity (an inertial cavita-
tion “dose”) has been established.78–81 This cor-
relation is so robust that hemolysis can be used
as a cavitation dosimeter.81,82 In blood contain-
ing ultrasound contrast agent gas bodies, expo-
sure to 1-MHz ultrasound with a 2.0-MPa PRPA
produces detectable hemolysis and inertial cav-
itation dose with pulses as brief as 2 cycles.80
The inertial cavitation dose and hemolysis
evolve and reach limiting values very rapidly in
vitro as microbubbles are destroyed. Both end
points are influenced strongly by the PRPA,
with thresholds at 1 MHz of approximately 0.5
to 1 MPa.81 Hemolysis induced by inclusion of
contrast agents in ultrasound-exposed samples
has a very strong frequency dependence at
suprathreshold PRPAs.79,82,83 That is, the PRPA to
produce a given level of hemolysis increases with
frequency much faster than the f 0.5 frequency
dependence of the MI. The MI, therefore, has
poor predictive value for the magnitude of
observed hemolysis above the threshold.
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Suspended phagocytic cells, which have bound or
phagocytosed contrast agent gas bodies, are lysed
when exposed to megahertz-frequency acoustic
pressures within the capabilities of diagnostic
imaging machines.84,85 When the expansion phase
of the phagocytosed bubble oscillation exceeded
the cell’s ability to expand, cell membrane damage
was observed. For 3-µm-diameter gas bodies and a
2.25-MHz frequency, a 0.9-MPa pulse did not
appear to damage the membrane, while a 1.6-MPa
pulse resulted in membrane rupture.
Exposure of whole blood to 3.5-MHz ultra-
sound produced by a diagnostic ultrasound
scanner (MI = 1.9) induced platelet activation at
a high gas body concentration of Levovist.86
Killing of lymphocytes cosuspended with con-
trast agent gas bodies in vitro results from expo-
sure to low-amplitude (0.2-MPa PRPA, 20/180
cycles on/off) 2-MHz ultrasound in the rotating
tube system.87
4.2. In Vitro Studies of Bioeffects on Cell
Monolayers
Miller and Bao88 studied cell killing in Chinese
hamster ovary monolayers insonified in the pres-
ence of Albunex. Monolayers were exposed to 10-
microsecond pulses of 3.3-MHz ultrasound
while “inverted” (ie, the monolayer was located
at the top of the vessel during exposure so that
the gas bodies would rise to become adjacent to
the monolayer). This model system was designed
to maximize the potential for cellular effects and
may simulate the concentration of gas bodies at
a distal vessel wall by acoustic radiation forces.89
A second transducer was used to detect subhar-
monic emissions associated with oscillating bub-
bles. Cell killing and bubble acoustic emissions
were correlated with the PRPA, with a threshold
of 0.56 MPa. Similar experiments using Optison
and 3.5-MHz diagnostic ultrasound showed epi-
dermoid cell sonoporation to be strongly depen-
dent on gas body concentration.90 Sonoporation
was detected at PRPAs as low as 0.23 MPa in the
pulsed Doppler mode and 0.39 MPa in the B-
mode. Experiments to characterize gene transfer
and cell killing were conducted with similar
inverted epidermoid cell monolayers and used a
diagnostic scanner operating in the harmonic
mode (1.5-MHz transmit frequency) to produce
the ultrasound exposures. With 2% Optison, the
PRPA threshold for cell killing was less than 0.7
MPa, and gene transfer was detected above 1.7
MPa.91
Brayman et al76 modeled the endothelial layer
of blood vessels with V79 fibroblast monolayers
whose orientation was varied to simulate either
the proximal or distal walls of blood vessels
scanned by ultrasound. Contrast agents
increased damage to both distal and proximal
monolayers at 1.0-, 2.1-, and 3.5-MHz frequen-
cies with a sharp frequency dependence (Figure
1). Distal monolayers were damaged more than
proximal monolayers. Kudo et al92 used a high-
speed camera to directly observe ultrasound-
induced (1 MHz, 0.6-MPa PRPA) oscillations of
618 J Ultrasound Med 2008; 27:611–632
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Figure 1. Critical (apparent threshold) measurements of the
PRPA for cell damage by pulsed ultrasound interaction with con-
trast agent gas bodies in in vitro test systems. Circles74 are fitted
by line A for hemolysis in a whole-blood suspension with
Albunex. Triangles are for hemolysis with an Albunex (top) or
Optison (bottom) suspension in whole blood.75 Line B is for ero-
sion of endothelial-like cell monolayers by pulsed ultrasound
interaction with Albunex suspended in the medium.76 Filled dia-
monds72 are fitted by line C for killing of phagocytic monolayer
cells with Optison gas bodies attached to the cells. Open dia-
monds represent apparent thresholds for cell killing (top) and
sonoporation (bottom) of epidermoid cells with Optison gas
bodies allowed to rise and contact the monolayer cells.77
Reproduced with permission from Miller D. Overview of experi-
mental studies of biological effects of medical ultrasound caused
by gas body activation and inertial cavitation. Prog Biophys Mol
Biol 2007; 93:314–330.
contrast agent gas bodies adjacent to bovine
endothelial cell monolayers. Obvious cell shape
distortions and killing were associated with non-
spherical bubble collapse.
Phagocytic cell monolayers (RAW-264.7) prein-
cubated with Optison and then washed to
remove unbound gas bodies were killed by expo-
sure to ultrasound produced by a diagnostic
ultrasound machine operated in the spectral
Doppler mode, with a PRPA threshold of approx-
imately 0.2 MPa.77 Similar experiments using
Optison showed the PRPA threshold to be 0.8
MPa for exposures consisting of a single 2-cycle
pulse.72 Using 2-cycle ultrasound pulses, the
PRPA thresholds for killing RAW-264.7 cells
preloaded with Optison showed a linear correla-
tion (r2 = 0.982) with frequencies over the 1- to
10-MHz range (Figure 1), increasing with a slope
of approximately 0.06 MPa/MHz.73 The authors
note that these pressure thresholds are lower
than those for nucleation of inertial cavitation
and have a markedly different frequency depen-
dence. As noted above in section 3, the frequen-
cy dependence of gas body destabilization and
cellular bioeffects observed for this in vitro sys-
tem can be modeled by the theory for shell
stresses and acoustic microstreaming shear
stress on cells.59 The theory substantiated the
observed linear dependence of thresholds on
frequency. Owing to the design of this model
monolayer system for maximum sensitivity for
cellular bioeffects, the thresholds observed may
approximate the lowest PRPAs for which biolog-
ically significant bioeffects (ie, cell killing) can be
expected for contrast-aided pulsed ultrasound.
5. In Vivo Studies of Bioeffects 
In this section, available reports on in vivo bioef-
fects associated with contrast ultrasound will be
reviewed. Some reports of bioeffects at high
pulse amplitudes, which did not involve actual
diagnostic ultrasound or pulsed ultrasound
intended to simulate diagnostic ultrasound, are
briefly noted to indicate the types of bioeffects
that might occur above the guideline upper lim-
its for diagnostic ultrasound. Results of clinical
research conducted during the approval process
are generally not available for review. In addition,
research on possible pharmacologic side effects
(ie, without ultrasound interaction) of the con-
trast agents are not reviewed here. No epidemio-
logic studies are available on possible adverse (or
favorable) health effects of the use of ultrasound
contrast agents. Most in vivo research has been
conducted using mice or rats. Reports have cen-
tered mostly on skeletal or cardiac muscle, as
listed in Table 1. Several studies on other tissues
are listed in Table 2. Research on the possible
therapeutic use of diagnostic ultrasound aided
by gas bodies is also reviewed briefly.
5.1. Skeletal Muscle and Myocardium
The behavior and resulting bioeffects of contrast
agent gas body destruction by diagnostic ultra-
sound were observed by intravital microscopy of
the spinotrapezious muscle in rats.93 The muscle
was positioned in a custom-built chamber filled
with Ringer’s solution containing adenosine for
vascular dilation and propidium iodide to stain
nuclei of dead cells. A phased array diagnostic
ultrasound system was used in the harmonic
mode at 2.3 MHz to image the muscle. Optison
with fluorescently labeled gas bodies was
infused into the femoral vein for 1 minute before
obtaining a single image frame at a specific MI,
with MIs of 0.4, 0.5, 0.7, and 1.0 used for each ani-
mal. After exposure, the muscle was examined
for microvessel rupture and dead (stained) cells.
The number of capillary rupture sites and
stained cells was near 0 at an MI of about 0.4 and
increased rapidly for the higher MI values.
The induction of petechiae by contrast-aided
diagnostic ultrasound was confirmed for skeletal
muscle by Miller and Quddus.94 A 2.5-MHz
probe was directed at the abdomens of anes-
thetized mice mounted in a water bath to pro-
vide for free-field exposure conditions. A
tissue-mimicking phantom was used to simulate
intervening tissue. Evans blue dye, used to indi-
cate microvascular leakage, and Optison were
introduced by retro-orbital injection. After imag-
ing, the abdominal muscle and intestines were
examined for microvascular injury. For 10 peri-
ods with 10 seconds on and 10 seconds off with
5-mL/kg Optison, petechiae counts in the tissue
were significantly elevated relative to shams at
PRPAs above 0.64 MPa (measured equivalent MI
= 0.4) and were proportional to the square of the
PRPA. A single image frame was sufficient to pro-
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duce petechiae. The petechiae number was
approximately proportional to the contrast agent
dose. Evans blue leakage was evident, and excess
dye could be extracted from tissue within the
scan plane relative to sham samples. Miller and
Quddus94 also reported capillary rupture in fat,
small intestine, and Peyer patches (intestinal
lymph nodes).
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Table 2. Bioeffects of Diagnostic or Pulsed Ultrasound With Contrast Agents in Various Tissues Other Than Muscle
Frequency, 
Reference MHz Mode Agent Animal Tissue Effect Critical MI
Miller and Gies106,107 1.09 10-µs pulses Albunex, Levovist Mouse intestine Petechiae 0.81
2.3 Optison, PESDA 1.2
Kobayashi et al108 1.8 Harmonic Levovist Intravital rat Endothelial cell killing ≈0.61 only
B-mode mesentery
Schlachetzki et al109 2.0–3.5 Transcranial Levovist, Optison Human brain Negative for magnetic <1.9
color duplex resonance contrast leakage
Wible et al110 1.8 Continuous or Optison, MP1950 Rat kidney Glomerulus, hemorrhage 0.94
4.0 triggered B-mode MP2211 1.0
Kobayashi et al101 1.8 Harmonic B-mode Definity, Levovist Intravital rat Endothelial cell killing, ≈0.1
mesentery hemorrhage 
Shigeta et al86 8 B-mode Levovist Rat liver Platelet aggregation, ≈1.8 only
12 endothelial injury ≈0.7 only
O’Brien et al111 3.1 1.2-µs pulses Optison Rat lung Negative for enhanced 1.6, 3.3
hemorrhage
Miller and Dou112 1.5 Harmonic B-mode Definity Mouse tumor Negative for enhanced 1.9 only
metastasis
*The different MI values correspond to the different frequencies.
Table 1. Bioeffects Induced by Contrast-Aided Diagnostic Ultrasound in Skeletal and Cardiac Muscle
Frequency, 
Reference MHz Mode Agent Animal Tissue Effect Critical MI
Skyba et al93 2.3 B-mode Optison Rat spinotrapezius Microvessel rupture, ≈0.4
cell killing
Miller and Quddus94 2.5 B-mode Optison Mouse abdominal Petechiae, capillary 0.4
leakage
van der Wouw et al95 1.66 Triggered B-mode AIP101 Human heart PVCs 1.1–1.5
Ay et al96 1.8 Triggered B-mode PESDA, Rabbit isolated Function, lactate, 1.0
Sonazoid, heart capillary rupture
Optison, 
Levovist
Chen et al97 1.3 Triggered B-mode Optison, Rat heart Troponin T elevation, ≈1.2
Definity negative histologic 
findings
Borges et al98 1.7–1.9 Triggered B-mode Optison Human heart Negative for PVCs, 1.4–1.7 only
troponin I, CK, 
CK-MB
Raisinghani et al99 NS Triggered Doppler PB127 Human heart Negative for PVCs <1.0
Li et al100 1.7 Triggered B-mode Optison Rat heart PVCs 0.77
Petechiae, leakage 0.41
Kobayashi et al101 1.8 Harmonic B-mode Definity Rat heart Negative for petechiae ≈0.61 only
Miller et al102 1.7 Triggered B-mode Optison Rat heart Microvascular leakage 1.5 only
<20 min
Li et al103 1.7 Triggered B-mode Optison, Rat heart PVCs 0.77
Imagent, Petechiae 0.31
Definity
Miller et al104 1.5 Triggered B-mode Optison Rat heart Histologic microlesions 1.7 only
Chapman et al105 1.7 Triggered B-mode PESDA Human heart PVCs, arrhythmia <0.8
NS, not specified.
620 J Ultrasound Med 2008; 27:611–632
Increased numbers of premature ventricular
contractions (PVCs) were reported in humans
undergoing contrast echocardiography by van
der Wouw et al.95 The contrast agent AIP101
(not commercially available) was infused intra-
venously into healthy volunteers. Cardiac
scans were conducted at 1.66 MHz with inter-
mittent image frames, which allowed refill of
the tissue with the contrast agent between
frames, and MI values of 1.1 and 1.5. A signifi-
cant increase in PVCs to about 1 per minute
was seen for end-systolic triggering at an MI of
1.5 but not at an MI of 1.1.
The microvascular effects of contrast echocar-
diography were examined in isolated rabbit
hearts by Ay et al.96 A cardiac ultrasound system
was operated at 1.8 MHz with 1-Hz triggering of
image frames using the machine display MI as a
measure of the exposure. The perfusate con-
tained the laboratory-made perfluorocarbon-
exposed sonicated dextrose albumin (PESDA)
contrast agent (effects were also confirmed with
commercial agents); however, it is difficult to
relate the dosage to an in vivo intravenous dose.
Scanning at an MI of 1.6 led to a transient
decrease in left ventricular pressure. Lactate
release was significant at MIs of 1.0 and higher.
Light microcopy revealed capillary damage and
erythrocyte extravasation.
Potential injurious effects associated with the
use of Optison or Definity with diagnostic ultra-
sound exposure were examined for in vivo rat
hearts.97 Imaging was performed at 1.3 MHz with
electrocardiographic (ECG) triggering at every 4
cardiac cycles. The contrast dosage was 0.1 mL in
saline delivered by infusion into the jugular vein.
Left ventricular function was not perturbed
(maximum MI = 1.6). Elevations in troponin T in
blood plasma, indicating myocardial damage,
were detected after 30 minutes for MIs of 1.2 and
1.6. The elevation was significant at an MI of 1.6
for both agents, declining to normal by day 4.
Histologic examination of scanned tissue
obtained on day 7 did not show evidence of
necrosis, vascular damage, or inflammation.
A clinical study was reported for humans
undergoing MCE by Borges et al.98 A dose of 3 mL
of Optison in saline was injected as a bolus into
the cubital vein over 3 minutes followed by a
saline flush. A diagnostic scanner was used in the
harmonic imaging plus power Doppler imaging
duplex mode at 1.7 to 1.9 MHz for MIs of 1.4 to
1.7 and with end-systolic triggering at every 1 to
3 beats. Blood samples were taken before and up
to 24 hours after scanning and were analyzed for
myoglobin, troponin I, creatine kinase (CK), and
CK isoenzyme MB. One patient had a transient
increase in troponin I after the examination, but
there were no consistent changes in measured
parameters that could be related to the ultra-
sound examinations.
A large group (135) of humans was studied with
regard to induction of PVCs during MCE using a
new contrast agent, PB127.99 Several cardiac
ultrasound machines were used in the dual-
frame triggering mode with MI settings of 0.9 to
1.0. One group of patients also had dipyridamole
infusion for a stress test. Premature ventricular
contractions were observed in the patient group
but were not associated with the frame triggers.
There was no significant increase in PVC fre-
quency during or after imaging. The negative
result was reassuring, but higher MI values
would have been needed for direct comparison
with the results of van der Wouw et al.95
An in vivo rat model of MCE was used to exam-
ine microvascular permeabilization and PVCs
with respect to the method of imaging, ultra-
sound exposure, and agent dose.100 A 1.7-MHz
diagnostic ultrasound system was used to scan
the rats in a water bath for 3 minutes. Evans blue
dye, a marker for microvascular leakage, and a
bolus of Optison were injected intravenously.
Neither PVC nor microvascular leakage was seen
in controls, rats imaged without the injected
contrast agent, or rats with the injected contrast
agent but not imaged. Triggering 1:4 at end sys-
tole produced the most PVCs, petechiae, and
microvascular leakage, followed by end systole
1:1 triggering, continuous scanning, and end
diastole 1:1 triggering. All effects increased with
increasing Optison doses over the range of 25 to
500 µL/kg. Threshold PRPAs above which effects
were significant were 1.0 MPa for PVCs and 0.54
MPa for microvascular leakage.
The possible occurrence of microvascular
injury to rat hearts was also examined by
Kobayashi et al.101 A phased array ultrasound
system was used at 1.8 MHz and a 4-cm focus
with frame rates and on-screen MI combina-
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tions of 1.6 and 1 Hz, 0.2 and 30 Hz, and 1.6 and
30 Hz. After scanning of the rat mesentery,
described below, the probe was moved to the
chest wall for 3 minutes of exposure while
Definity at 0.1 or 1.0 mL/kg was administered.
This arrangement may have placed the rat heart
in the near field of the array (ie, at lower PRPAs
than implied by the on-screen MI), but the heart
images were monitored on the ultrasound
screen. After scanning, the hearts were fixed for
histologic examination. No hemorrhages were
found in the rat heart sections.
The timing and influence of vasoactive drugs on
microvascular leakage induced by MCE in rats
were investigated by Miller et al.102 Hairless rats
were anesthetized and transthoracically scanned
with a diagnostic ultrasound system (GE VingMed
System V) at 1.7 MHz with 1:4 triggered frames at
end systole in a water bath with the heart at the
focal position. Optison, vasoactive medications,
and Evans blue dye were injected via the tail vein.
Effects were similar to those in the previous
study.100 Propranolol and isoproterenol had little
effect on the microvascular leakage, which sug-
gests that the microvascular leakage was primarily
a mechanical effect rather than a physiologic
response. Capillary leakage occurred during and
after exposure but diminished for Evans blue injec-
tions administered 20 minutes after scanning.
The effects of PVCs, petechiae, and microvascu-
lar leakage reported by Li et al100 were compared
for Optison, Definity, and Imagent.103 On the basis
of the volume dose, MCE using Definity produced
more microvascular leakage. An example of the
petechial hemorrhages and microvascular leakage
seen in rat hearts after Definity MCE is shown in
Figure 2. However, when expressed in terms of the
number of gas bodies, there was no apparent dif-
ference between the three agents’ microvascular
damage potential, which increased linearly with
the gas body dose at low doses, as shown in Figure
3. Myocardial contrast echocardiography using
Definity resulted in fewer PVCs than the other
agents. The effects increased strongly with the
PRPA, with calculated thresholds for petechiae at
about 0.4 MPa (MI = 0.31) and for PVCs at about 1.0
MPa (MI = 0.77). The was no apparent threshold for
the visual detection of an Evans blue leakage area
on the heart surface, which was significant for the
lowest exposure of 0.54 MPa (MI = 0.41).
Histologically defined microlesions with
inflammatory cell infiltration induced by MCE
were reported by Miller et al.104 Myocardial con-
trast echocardiography with 1:4 end-systolic
triggering was performed in rats at 1.5 MHz and
an MI of 1.7 in a short-axis view of the left ventri-
cle in rats. Two high doses (500 µL/kg) of Optison
were given 5 minutes apart during 10 minutes of
echocardiography. In rats killed 10 minutes after
MCE, microvascular leakage and petechiae were
evident. After 24 hours, microlesions with inflam-
matory infiltrates were scattered primarily over
the anterior half of the sections. Lesion areas in
the anterior wall were scored from photomicro-
graphs, and there was inflammatory cell infiltra-
tion in areas of 0.5% ± 0.8% (SD) for shams and
7.4% ± 5.0% for MCE (P < .02). For rats killed 1
and 6 weeks after MCE, the microlesions healed
to form small fibrous regions interspersed with
normal myocytes.
Dalecki et al113 examined the induction of pre-
mature contractions in mice by 1.2-MHz pulsed
ultrasound with Albunex or Optison in the circu-
lation. Pulses were triggered during diastole
from the ECG. Using 5-millisecond pulses, the
threshold for premature contractions was low-
622 J Ultrasound Med 2008; 27:611–632
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Figure 2. Microvascular leakage of Evans blue dye and petechial
hemorrhages in a rat heart model of MCE.103 Diagnostic B-mode
ultrasound at 1.7 MHz with an in situ PRPA of 1.9 MPa (MI ≈ 1.5)
was used to image the heart using frame triggering at end-sys-
tole at each fourth heartbeat. A bolus of Definity at the recom-
mended dose of 10 µL/kg was injected into the tail vein with
scanning continuing for 5 minutes after contrast appeared in the
heart. Scale bar indicates 2 mm. Reproduced with permission
from Miller D. Overview of experimental studies of biological
effects of medical ultrasound caused by gas body activation and
inertial cavitation. Prog Biophys Mol Biol 2007; 93:314–330.
ered by a factor of 10 below a previously deter-
mined threshold without the contrast agent to
about 0.2 MPa, which suggests that cavitation
was responsible for the bioeffect. For 10-
microsecond pulses, the threshold was about 1
MPa. The thresholds were similar for the two dif-
ferent agents.
The occurrence of arrhythmias, such as PVCs,
was examined and compared for physical thera-
py ultrasound and for triggered diagnostic ultra-
sound in humans.105 The therapeutic mode
involved an unfocused 1-MHz ultrasound beam
with continuous or burst mode operation at
measured PRPAs up to only 0.39 MPa. The diag-
nostic ultrasound machine was operated at 1.7
MHz with frames triggered at every 4 cardiac
cycles and had a measured PRPA of 1.0 MPa for a
1.3-MI setting on the machine. The therapy
device produced significantly more arrhythmia
than the diagnostic imager for the same
transthoracic exposure windows for the heart,
which indicates that factors other than PRPA,
such as a continuous versus pulsed mode, are
important for this bioeffect. The low numbers of
PVCs induced by the diagnostic ultrasound with
a moderate PRPA,
was consistent with other observations in
humans95 and also in rats.103
5.2. Bioeffects on Other Tissues
The intestine has been of interest with regard to
potential nonthermal bioeffects, owing to its nat-
ural content of free gas bubbles. Miller and
Gies106,107 used pulsed ultrasound to simulate
diagnostic ultrasound (10-microsecond pulses
and a 1-kHz pulse repetition frequency for 100
seconds) to expose mouse intestines and search
for petechiae in the intestinal wall. Contrast
agents were introduced by retro-orbital injection.
Peak rarefactional pressure amplitude thresholds
for induction of petechiae in the presence of 10-
mL/kg Albunex increased from 0.85 MPa at 1.09
MHz to 2.3 MPa at 2.4 MHz. Levovist, Optison,
and PESDA all yielded more petechiae than
Albunex at 2.3 MHz, and thresholds were as low as
1.8 MPa (MI ≈ 1.2) for Levovist. Owing to the con-
tinuous exposure in the near field of unfocused
transducers, the apparent thresholds are not com-
parable to intermittent diagnostic scanning.
The occurrence of microvascular injury to the
rat mesentery was examined by Kobyashi et al108
using diagnostic ultrasound in an intravital
preparation. A phased array ultrasound system
was used at 1.8 MHz and a 4-cm focus with
frame rates and MI combinations of 1.6 and 1
Hz, 0.2 and 30 Hz, and 1.6 and 30 Hz. Field mea-
surements indicated a PRPA of 0.82 MPa (MI ≈
0.61). Levovist was injected via the femoral vein.
Propidium iodide was used to stain venule and
capillary endothelial cells killed by contrast-
aided scanning. Capillary ruptures were rare.
This same system was used to compare Levovist
with Definity for induction of endothelial cell
injury and microvessel bleeding.101 The system
was adjusted for a measured PRPA value of either
0.14 MPa (MI ≈ 0.1) or 0.82 MPa (MI ≈ 0.61). No
microvessel injury was seen for either ultrasound
alone or the contrast agent alone. Microvessel
bleeding was rare and only seen for the 30-Hz
frame rate at the higher exposure. Endothelial
cell damage was observed for all conditions at
the higher exposure. Significant cell killing was
produced using the low exposure and 30-Hz
8.0<
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Figure 3. Comparison of the counts of petechiae seen on the rat
heart surface after MCE at 1.7 MHz, 1:4 end-systolic triggering,
and a PRPA of 1.9 MPa. The doses of the three agents are com-
pared on the basis of the numbers of gas bodies in the bolus
injections. The curves are simple exponential functions with lin-
ear dependence at low doses and saturation at higher doses.
Reproduced with permission from Li P, Armstrong WR, Miller DL.
Impact of myocardial contrast echocardiography on vascular
permeability: comparison of three different contrast agents.
Ultrasound Med Biol 2004; 30:83–91.
frame rate with 1.0-mL/kg Definity in capillaries
and venules (but not arterioles).
The possible alteration of the blood-brain
barrier by contrast-aided ultrasound was inves-
tigated by Schlachetzki et al.109 Transcranial
color-coded sonography was performed on
human volunteers with a 2- to 3.5-MHz phased
array probe with maximal output settings.
Frames were triggered from the ECG at each
heartbeat, with speckling in the color Doppler
images indicating microbubble destruction.
Levovist and Optison were used for the con-
trast ultrasound, and the magnetic resonance
contrast agent Magnevist (Bayer HealthCare
Pharmaceuticals, Leverkusen, Germany) was
also injected intravenously. Evidence of
microvascular leakage was sought using mag-
netic resonance imaging of the brain. There were
no indications of focal signal enhancement
attributable to extravasation of the Magnevist.
Wible et al110 studied renal capillary hemor-
rhage induced by contrast ultrasound in rats. A
diagnostic ultrasound probe was placed 1 cm
from the kidney with one kidney exposed at a 30-
Hz frame rate and the other at a 1-Hz frame rate.
Frequencies of 1.8, 4, and 6 MHz were used at
displayed MI values of 0.4 to 1.6, with the actual
PRPA values measured at 1.5 cm. The contrast
agents MP1950, MP2211, and Optison were
administered at a dose of 40 million microbub-
bles/kg. Contrast-aided ultrasound caused areas
of small hemorrhages visible on the kidney sur-
face within the scanned plane. The small hemor-
rhages involved escape of red blood cells from
the glomerular tuft into the Bowman capsule and
proximal convoluted tubules. Intermittent expo-
sure was more effective at producing the small
hemorrhages than continuous scanning and
gave a significant increase in renal hemorrhages
for a PRPA of 1.26 (MI = 0.94). The severity
decreased with increasing ultrasound frequen-
cies but was significant at a PRPA of 2.02 at 4 MHz
(MI = 1.0). At 6 MHz, no significant hemorrhagic
effect was seen, but the maximum measured
PRPA was only 1.6 MPa (MI = 0.65).
The liver is often the subject of ultrasound
examinations, and these can be improved by
contrast agents. Effects of Levovist-aided ultra-
sound on rat liver were investigated by Shigeta et
al.114 The on-screen MI values were 1.8 at 8 MHz
and 0.7 at 12 MHz, and both were used on each
rat. The transducers were moved to expose the
entire liver. Electron microscopy was performed
on the rat livers with control, sham, and ultra-
sound-only groups and two groups with ultra-
sound plus contrast, 1 killed immediately and the
other killed 5 hours later. Qualitative observation
of the specimens revealed platelet aggregation in
the liver sinusoids for ultrasound-only and ultra-
sound-plus-contrast groups. Endothelial cell
damage was seen in the ultrasound-plus-con-
trast group with the 5-hour delay.
Pulsed ultrasound has been shown to induce
lung hemorrhage under some conditions, but
the exact mechanism is not clear. O’Brien et al111
tested the hypothesis that cavitation was the
mechanism by using saline or Optison injection
with pulsed ultrasound exposure. Ten-second
exposures were performed on rats at 3.1 MHz
with 1.2-microsecond pulses and a 1-kHz pulse
repetition frequency and in situ PRPAs of 2.74
and 5.86 MPa (equivalent to in situ MI values of
1.6 and 3.3, respectively). The contrast agent
groups did not have an increase in lung lesion
occurrence or size relative to the saline groups,
which suggests that microbubble cavitation was
not the mechanism for the lung hemorrhage.
This finding confirms an earlier test using
Albunex.115
Contrast-aided ultrasound scanning of various
tissues can assist in the identification of malignant
tumors but might cause microvascular perturba-
tions. Melanoma tumors growing on the thighs of
mice, which undergo metastatic spread to the
lungs, were scanned with 1.5-MHz diagnostic
ultrasound during or after Definity injection.112
Image frames were triggered at a 1-Hz rate, and
four 10-µL/kg retro-orbital injections of the con-
trast agent were made over a 100-second expo-
sure. Sham exposure involved scanning for 100
seconds followed by Definity injection with the
ultrasound off. For ultrasound plus the contrast
agent, observation of a brightening of the tumor
image confirmed the interaction of ultrasound
with the contrast agent within the tumor. One day
after scanning, the primary tumor was surgically
removed, and the possible lung metastasis was
allowed to develop for 28 days. No significant
increase in lung metastases was seen in the lungs
for the contrast-aided ultrasound group. 
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5.3. Bioeffects Above the Diagnostic Limit
Several researchers have studied bioeffects of
ultrasound contrast agents with pulsed ultra-
sound (for which cavitation might not normally
occur) that had pressure amplitudes greater than
the US FDA guideline upper limit for diagnostic
ultrasound. Miller and Gies116 injected hairless
mice with Albunex and exposed the abdominal
region to lithotripter shock waves. An increase in
mortality was found after exposure to several
hundred shock waves, with increasing mortality
for increasing Albunex doses. Hynynen et al117
found that 1.63-MHz focused ultrasound with
10-microsecond pulses at 6.3 MPa produced his-
tologically observable tissue damage in rabbit
brains. For this work, a window was created in
the skull for exposure, and a bolus of Optison
was injected 10 seconds before exposure. Hwang
et al118 examined effects of pulsed 1-MHz ultra-
sound on rabbit ear veins with Optison in the cir-
culation. Vessel wall damage with Evans blue
extravasation was increased by the contrast
agent at 6.5 MPa, and a small percentage of the
endothelial surface was damaged at 3.35 MPa
with the contrast agent. Hemolysis in suspen-
sions has been studied for many years as an indi-
cator of cavitation bioeffects. Dalecki et al119
detected hemolysis in vivo in mice with Albunex
in the circulation. For a 10-microsecond pulsed
exposure of the heart, thresholds were 3.0 MPa
(peak positive or 1.9-MPa negative pressure
amplitude) at 1.15 MHz but in excess of 10 MPa
(peak positive) at 2.35 MHz.
The capillary hemorrhage effect was studied in
mice injected with 0.1 mL of Albunex using pos-
itive or negative pulses from an endoscopic
lithotripter (≈0.4 MHz).120 One hundred pulses of
3.6 or –3.6 MPa in amplitude were delivered to
the mouse abdomen. The negative pulses were
significantly more effective than the positive
pulses in producing hemorrhage in various tis-
sues, including kidney, intestine, muscle, and
stomach, which showed that the hemorrhage
resulted from inertial cavitation.
Premature complexes (ECG signals represent-
ing ventricular electrical activity) were seen for
10 of 20 rats exposed to 3.1-MHz ultrasound with
1.3-microsecond pulses at 15.9 MPa and Optison
in the circulation.121 However, myocardial
degeneration was identified by histologic stain-
ing in 16 rats, which suggests that the presence of
myocardial degeneration alone was not a suffi-
cient explanation of the premature complexes. 
5.4. Potential Therapeutic Applications
Contrast-aided ultrasound is capable of induc-
ing a variety of in vivo bioeffects, and some of
these effects may have useful clinical applica-
tions for therapy. There have been many reports
of high-power contrast-aided ultrasound use for
gene therapy, thrombolysis, and surgical appli-
cations, which will not be considered here. In
this document, only reports of in vivo therapeu-
tic applications that have involved actual diag-
nostic ultrasound systems for treatment are
noted. These reports do not directly address the
problem of bioeffects risks in diagnosis and often
involved special gas body agents (they are not
listed in Tables 1 and 2), but they have a bearing
on the perceived significance of the possible
effects.
The contrast ultrasound-induced effect of vas-
cular permeabilization has been suggested as a
means of drug delivery from the blood pool to
the interstitium.122 The method can accommo-
date small particles as well as molecular drugs.
Drug delivery was aided by Optison and was
targeted to skeletal muscle by 2.3-MHz diagnos-
tic ultrasound, which served both as an image
guidance device and as the ultrasound exposure
system.
Sonoporation, which is defined as transient
ultrasound-induced enhancement of cell mem-
brane permeability, has been used in applica-
tions of gene and drug delivery. Pislaru et al123
used a phased array transducer of a commercial
ultrasound imaging system (GE VingMed System
V) in in vitro and in vivo experiments. For in vivo
experiments, Sprague-Dawley male rats were
exposed with a 1.7-MHz diagnostic ultrasound
system and PESDA to transfect skeletal muscle
with the luciferase marker plasmid. Tissue sam-
ples were also taken from remote, noninjected
muscle or from the liver, kidney, lung, and
heart. Luciferase activities were about 10-fold
higher than with intramuscular injections of the
plasmid alone. Cationic lipid-DNA complexes
incorporated into microbubbles have also been
tested for DNA transfer in skeletal muscle.124
Diagnostic ultrasound at 1.75 MHz was used in
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the B-mode with in situ PRPA values of 1.04 to
1.14 MPa. The luciferase marker gene was used,
and gene expression was assessed after 4 days.
Intramuscular injection of the plasmid alone
produced strong gene expression, which was
matched by the intra-arterial treatment with
plasmid-loaded microbubbles and ultrasound.
No luciferase expression was seen outside the
ultrasound-treated region in liver or lung tissue
or in muscle treated with ultrasound and the
plasmid intra-arterially but without enhance-
ment of cavitation by added microbubbles.
Gene delivery to the myocardium of rats was
enhanced by treatment with harmonic mode
diagnostic ultrasound, a microbubble contrast
agent, and a viral β-galactosidase vector.125 The
contrast agent was prepared in the laboratory
and was processed with the vector to attach the
virus particles to the microbubbles. Three
frames from a 1.3-MHz transducer destroyed the
microbubbles evident in the second-harmonic
image, and 3 frame bursts were triggered inter-
mittently to allow refill of the tissue between
scans. The hearts of all animals that received the
combined ultrasound plus microbubble treat-
ment showed expression of the transgene.
Vannan et al126 used cationic microbubble-
linked plasmids and diagnostic ultrasound
exposure to enhance transfer of the chloram-
phenicol acetyltransferase (CAT) marker gene in
dog hearts. Diagnostic ultrasound was delivered
into anesthetized closed-chest dogs at 1.3 MHz
and the highest power settings (MI = 1.5–1.7).
Multiple frames were triggered at every 4 to 6
cardiac cycles in an apical 4-chamber view. The
specially prepared microbubbles were injected
into a cephalic vein. For ultrasound with the
plasmid-loaded microbubbles, CAT expression
was found in several regions of the heart, with
303 ± 188 ng/g in the myocardium for 4 dogs.
However, for the ultrasound treatment of the
heart only, CAT expression was found in distant
tissues of the lungs, liver, kidney, and skeletal
muscle.
Ultrasound-enhanced gene transfer to cardiac
tissue was also shown using albumin and lipid
microbubbles containing a luciferase plas-
mid.127 The agents were infused for 20 minutes
through the jugular vein of anesthetized rats,
and the hearts were scanned with a 1.3-MHz
cardiac ultrasound machine at an MI of 1.5 with
4 frames triggered from the ECG at every 4 car-
diac cycles. Luciferase expression after 4 days
was primarily detected in the heart, with some
gene expression evident in the liver for the albu-
min microbubbles and in the pancreas for the
lipid microbubbles. The echocardiographic
treatment parameters were varied to find the
optimum treatment conditions for the aden-
ovirus- or plasmid-modified contrast agent
microbubbles.128 Cardiac scanning was per-
formed in anesthetized rats to transfer the
luciferase plasmid. Triggered imaging at 1.3
MHz was more effective than continuous imag-
ing for gene transfer to the heart. An increase of
the MI from the normal maximum of 1.6 for the
diagnostic machine used in the study to 2.0 pro-
duced significantly greater gene transfer (the
FDA guideline upper limit for diagnostic ultra-
sound is MI = 1.9).
Myocardial infarction might be treated by
angiogenic gene therapies. Zhigang et al129 used
ultrasound to enhance DNA transfer of a gene
vector coding for vascular endothelial growth
factor in a rat model of myocardial infarction.
An albumin-based contrast agent was mixed
with a plasmid and incubated to attach the
plasmid to the microbubbles. Three days after
infarction, the plasmid vehicle was injected via
the tail vein and targeted to the heart by 1.8-
MHz echocardiography at the maximum MI
with ECG triggering at every 6 to 8 beats. A sta-
tistically significant increase in the microvascu-
lar density in the ischemic myocardium was
found in the ultrasound-plus-plasmid group.
The rat model of myocardial infarction was also
used by Kondo et al130 to test the efficacy of
gene therapy by hepatocyte growth factor. The
naked plasmid coding for hepatocyte growth
factor was injected through a catheter inserted
into the left ventricle, while the femoral vein
was used to infuse Optison microbubbles. The
treatment involved 1.3-MHz ultrasound trig-
gered in 3 frame bursts 1:8 at end systole at a
PRPA of 2.16 MPa. The capillary density in the
area around the infarct was 50% greater in the
contrast-plus-plasmid group than in control
groups, and staining for scar formation showed a
significantly smaller scar area.
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6. Conclusions
6.1. General Conclusions
Diagnostic ultrasound exposure can destabilize
contrast agent gas bodies (microspheres, or sta-
bilized microbubbles). In practice, the use of
high MI values (>0.8) involves rapid gas body
destruction, while use of low MI values (<0.2)
involves minimal gas body destruction. Physical
models of gas body behavior indicate that iner-
tial cavitation potentially can occur with expo-
sure conditions corresponding to MI values
greater than approximately 0.4, which therefore
represents a theoretical boundary between non-
inertial and inertial activity regimens. The com-
plex relationship between contrast agent
destabilization and inertial cavitation remains
the subject of active research.
In suspensions of nonphagocytic cells, the
dominant mechanism by which extensive cell
lysis is produced by ultrasound exposure with
contrast agents appears to be the occurrence of
inertial cavitation, and cavitation acoustic emis-
sions can be used as cavitation “dosimeters.” In
vitro studies have shown that diagnostic ultra-
sound exposures of very modest PRPAs can kill
attached monolayer cells when in contact with
contrast agent gas bodies. The cell injury can
occur below the inertial cavitation threshold,
apparently by a microstreaming shear stress
mechanism. Because contrast agent gas bodies
attach to phagocytic cells, these cells, which
constitute the mononuclear phagocytic system
in the body, may be particularly vulnerable.
However, conditions in the body are different
from specialized in vitro conditions, and transla-
tion of this basic research finding to in vivo con-
ditions is not possible at this time.
Studies of bioeffects induced by contrast-aided
diagnostic ultrasound in vivo, primarily in small
animals, have shown biologically significant
microscale effects, such as petechial hemor-
rhage with ultrasound exposures corresponding
to MI values above 0.4. This value agrees with the
theoretical threshold for inertial cavitation in
blood, which contains potential cavitation
nuclei. Additional information confirms that an
MI of 0.4 is an important boundary, as stated in
the American Institute of Ultrasound in
Medicine statement Bioeffects of Diagnostic
Ultrasound with Gas Body Contrast Agents.131
Above an MI of 0.4, bioeffects appear to increase
rapidly in magnitude, possibly as the square or
high-order exponent of the PRPA. The magni-
tude of effects appears to be proportional to the
contrast agent dose in terms of the number of
gas bodies for low doses. Reported bioeffects of
contrast-aided diagnostic ultrasound include
sonoporation, microvascular leakage, capillary
rupture (petechial hemorrhage), microlesions
with inflammatory cell infiltration, and PVCs
during ultrasound scanning. The bioeffects are
primarily in the form of scattered microscopic
injuries, which would not be expected to be clin-
ically detectable in the short term. An exception
is the induction of PVCs during contrast
echocardiography, which is clinically observable
but ceases on cessation of the ultrasound. The
longer-term medical significance of the reported
bioeffects is uncertain. Intentional bioeffects for
therapeutic purposes can be produced or
enhanced with diagnostic ultrasound exposure
of contrast agents, such as in gene therapy. No
epidemiologic studies are available on possible
adverse (or favorable) human health effects of
the clinical use of ultrasound contrast agents. 
6.2. Specific Conclusions 
1. Studies of bioeffects induced by contrast-
aided diagnostic ultrasound in vivo, primari-
ly in small animals, have shown bioeffects,
such as PVCs and petechial hemorrhage with
ultrasound exposures corresponding to MI
values above 0.4. This value agrees with the
theoretical threshold for inertial cavitation in
blood, which contains cavitation nuclei. 
2. Above an MI of 0.4 bioeffects appear to
increase rapidly in magnitude as the square
or higher exponent of the PRPA. The magni-
tude of effects appears to be proportional to
the concentration of gas bodies for concen-
trations at or below the manufacturers’ rec-
ommended dose.
3. In vitro studies have shown that diagnostic
ultrasound exposures can induce death of
attached monolayer cells when in contact
with contrast agent gas bodies. Cell injury
can occur below the inertial cavitation
threshold; the minimum reported thresh-
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olds for cell death were approximately p/f =
0.06 MPa/MHz.
4. Contrast agent gas bodies can be bound and
internalized by phagocytic cells, making
them particularly vulnerable to injury from
ultrasound exposure. The clinical implica-
tions, if any, of these results are unknown.
5. Inertial cavitation is the dominant mecha-
nism of cell lysis in whole blood exposed in
vitro or in vivo to diagnostic ultrasound in the
presence of contrast agents at suprathresh-
old pressure amplitudes. The clinical impli-
cations, if any, of these results are unknown.
6. Interaction of diagnostic ultrasound with
contrast agents is under investigation for
therapeutic applications.
7. Recommendations
1. For imaging with contrast agents at MIs
greater than 0.4, practitioners should use the
minimal agent dose, MI, and exposure time
consistent with acquisition of diagnostic
information. 
2. Practitioners of contrast-aided echocar-
diography should note that use of high MI
values (>0.8) involves rapid gas body
destruction with a potential for bioeffects
(eg, PVCs), whereas bioeffects have not
been observed at low values of   
(<0.2), which involve minimal gas 
body destruction.
3. The ECG should be monitored during
high-MI contrast cardiac-gated perfusion
echocardiography, particularly in patients
with a history of myocardial infarction or
unstable cardiovascular disease.* 
4. Output display indices represent important
information and should be documented as
part of the permanent record of the exami-
nation to enable future research. 
5. The initial setting of the MI at mode selec-
tion for contrast-aided ultrasound imaging
should be 0.4 or less.
6. Contrast-specific exposure indices should
be developed that reflect the destruction
thresholds and more accurately account for
the in situ exposure values (derating factor). 
7. Studies in laboratory animals are needed to
investigate the potential for ultrasound-
induced adverse fetal effects in the presence
of ultrasound contrast agents or other
exogenously introduced bubbles.
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